Bendamustine
Treanda · Alkylator
Tumor lysis-mediated AKI is the principal risk; TMA is rare.
PRETMALYTE
ModerateOpen →
Immunomodulatory drug (IMiD)
Thalidomide
Thalomid · THAL
The original IMiD, whose kidney risk is dominated by tumor lysis and reduced perfusion rather than direct nephrotoxicity.
MildImmunomodulatory drug (IMiD) · approved 2006
Multiple myelomaErythema nodosum leprosum
Signature kidney injury
Prerenal / Hemodynamic AKI
Thalidomide is not a direct nephrotoxin; the principal renal hazard is tumor lysis syndrome, which is uncommon in myeloma and reported at the case level. Sinus bradycardia is a recognized dose-related non-renal effect that, with the drug’s sedative/hypotensive properties, can compound prerenal physiology. Venous thromboembolism is the other dominant class toxicity.
Source: Chang et al., Chang Gung Med J 2011
Mechanism of kidney injury
Kidney injury is largely indirect: effective cytoreduction precipitates tumor lysis with hyperuricemia and hyperphosphatemia, producing urate/calcium-phosphate intratubular crystal deposition and a prerenal/AKI picture. Drug-induced bradycardia, sedation, and hypotension can reduce renal perfusion; thromboembolic events can rarely involve the renal vasculature.
Clinical presentation
Stable renal function in most patients; TLS presents with hyperuricemia, hyperkalemia, hyperphosphatemia, and rising creatinine. Bradycardia, constipation, somnolence, and peripheral neuropathy are characteristic non-renal effects.
Onset
Tumor lysis within days of initiation in high-burden disease; bradycardia over weeks of dosing.
Reversibility
Reversible
Anticancer mechanism
Parent immunomodulatory drug that binds cereblon, inhibits angiogenesis (VEGF/bFGF), modulates cytokines (suppresses TNF-alpha), and co-stimulates T/NK cells. Used in multiple myeloma and erythema nodosum leprosum.
Management
Manage tumor lysis with isotonic hydration, rasburicase/allopurinol, and electrolyte correction; address bradycardia/hypotension to preserve renal perfusion. Direct dose-limiting nephrotoxicity is not characteristic of thalidomide.
Risk factors
- High tumor burden
- Pre-existing renal impairment
- Volume depletion
- Bradycardia / reduced perfusion; concurrent rate-slowing or hypotensive drugs
Prevention
- Tumor-lysis prophylaxis (hydration, allopurinol or rasburicase) when indicated
- Monitor electrolytes, uric acid, and creatinine early
- Monitor heart rate for bradycardia; VTE prophylaxis per regimen
Note · Tumor lysis, bradycardia, and VTE are the salient issues; thalidomide itself is not a classic direct nephrotoxin.
Clinical depth
Renal dose adjustment
No specific renal dose adjustment is mandated (thalidomide is poorly renally cleared, eliminated largely by non-enzymatic hydrolysis); use cautiously and titrate to tolerance in advanced CKD. Dose on dialysis days after the session.
Dialyzability & ESKD dosing
Not significantly dialyzed in routine practice; no supplemental dosing required. Give after hemodialysis on dialysis days.
Differential diagnosis
As with the other IMiDs, separate TLS crystal nephropathy from prerenal azotemia and myeloma cast nephropathy; bradycardia-related hypoperfusion should be considered when AKI accompanies a low heart rate.
Monitoring
- Uric acid, potassium, phosphate, calcium, creatinine at initiation in high-burden disease
- Heart rate (bradycardia)
- Signs/symptoms of VTE
Key trials & series
- Coiffier et al. evidence-based TLS guidelines (class management)
Clinical pearls
- Thalidomide is not a classic tubular nephrotoxin - watch for tumor lysis, bradycardia, and VTE instead.
- Bradycardia plus hypotension can produce prerenal AKI; reassess perfusion before blaming intrinsic injury.
Where it strikes
Nephron segments
Vasculature / Endothelium
Glomerular & peritubular capillaries
Tubular Lumen
The urine flow path
Injury signatures
Prerenal / Hemodynamic AKIElectrolyte Wasting
Beyond the kidney
Class-level context for the major non-renal toxicities of immunomodulatory drug (imid)s.
Vascular
Hypertension, VTE/ATE, bleeding, aneurysm
- Venous thromboembolism
Hematologic
Cytopenias, thrombosis, TMA
- Myelosuppression
Neurologic
Neuropathy, encephalopathy, ICANS, PRES
- Neuropathy (thalidomide)
Evidence
6 peer-reviewed references. Citation metadata via PubMed / NLM.
LandmarkTumor lysis syndrome in patients with light chain multiple myeloma: report of two cases.Chang H et al. · Chang Gung Med J 2011 · PMID 22490464Tumor lysis syndrome during myeloma therapy including thalidomide.PMIDNew Agents in Multiple Myeloma: An Examination of Safety Profiles.Bringhen S et al. · Clin Lymphoma Myeloma Leuk 2017 · PMID 28601492Safety review noting thalidomide cardiac (bradycardia) and thromboembolic effects.PMIDGuidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review.Coiffier B et al. · J Clin Oncol 2008 · PMID 18509186Evidence-based TLS prophylaxis and treatment guidance relevant to IMiD-induced tumor lysis.PMIDLenalidomide and chronic lymphocytic leukemia.Gonzalez-Rodriguez AP et al. · Biomed Res Int 2013 · PMID 24163824Class context for IMiD-associated tumor lysis and tumor flare.PMIDNew drug toxicities in the onco-nephrology world.Perazella MA et al. · Kidney Int 2015 · PMID 25671763Onco-nephrology class context for novel-agent renal effects, including IMiDs.PMIDPomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials.Siegel DS et al. · Leuk Lymphoma 2016 · PMID 27267105IMiD renal-impairment context distinguishing thalidomide/pomalidomide handling from lenalidomide.
Related agents
Other agents sharing the same signature kidney injury.